FindTrial
Sign In

Comprehensive Analysis of Disease-Related Genes associated with Non-alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH); Study of Associations among the Disease-Related Genes and Serum Biomarkers and the Degree of Progression of NAFLD/NASH Pathology

Comprehensive Analysis of Disease-Related Genes associated with Non-alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH); Study of Associations among the Disease-Related Genes and Serum Biomarkers and the Degree of Progression of NAFLD/NASH Pathology - Comprehensive Analysis of Disease-Related Genes associated with NAFLD/NASH; Study of Associations among the Disease-Related Genes and Serum Biomarkers and the Degree of Progression of NAFLD/NASH Pathology

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014850
Enrollment
500
Registered
2014-12-01
Start date
2014-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic Fatty Liver Disease/ Non-alcoholic Steatohepatitis

Interventions

We will perform liver biopsy.

Sponsors

National Center for Global Health and Medicine, Department of Gastroenterology Kohnodai Hospital, Department of Gastroenterology The Research Center for Hepatitis and Immunology
Lead Sponsor
Yokohama City University School of Medicine, Department of Gastroenterology and Hepatology Tokyo Medical University, Department of Gastroenterology and Hepatology
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: NAFLD patients -Patients with a pathological diagnosis of NAFLD based on a liver biopsy Patients from whom consent has been obtained to participate in this study, which has been approved by the ethics committee.

Exclusion criteria

Exclusion criteria: a. Patients who have any other liver disease, such as chronic hepatitis C, chronic hepatitis B (HBs-Ag-positive patients), autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, alpha 1-antitrypsin deficiency, Wilson disease, or alcohol-related liver disease b. Patients who have a serious hepatic dysfunction, liver failure (encephalopathy, ascites, ruptured varices, or hyperbilirubinemia) c. Patients who have a serious renal dysfunction d. Patients who have a serious cardiopulmonary dysfunction e. Pregnant women, parturient women, breast-feeding women

Design outcomes

Primary

MeasureTime frame
We will conduct this study by performing comprehensive analysis of genes in NAFLD patients grouped according to the degree of histopathological progression in the liver and detect the genetic modifiers of NAFLD/NASH pathogenesis.—

Secondary

MeasureTime frame
We will comprehensively analyze each factor involved in fatty acid metabolism in each group by using blood serum and liver tissue collected. Then we assess their relationships with the genetic modifiers of NAFLD/NASH pathogenesis.—

Countries

Japan

Contacts

Public ContactYuichi Nozaki

National Center for Global Health and Medicine Department of Gastroenterology

fwix0777@nifty.com03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026